Adiposity markers and lung function in smokers: a cross-sectional study in a Mediterranean population by unknown
RESEARCH ARTICLE Open Access
Adiposity markers and lung function in
smokers: a cross-sectional study in a
Mediterranean population
Mar Sorlí-Aguilar1,2, Francisco Martín-Luján1,3,4*, Gemma Flores-Mateo2, Cristina Jardí-Piñana3,
Estefania Aparicio-Llopis3, Josep Basora-Gallisà2,3,5, Rosa Solà-Alberich3,6 and for the ESPITAP Study Group
investigators
Abstract
Background: The aim of this study was to assess the association of key adiposity markers with lung function in
smokers without respiratory disease in a Mediterranean population.
Methods: We performed a cross-sectional study with baseline data from a representative sample of the ESPITAP
study in Spain. Participants were 738 smokers (52.3% men) without respiratory disease, aged 35 to 70, selected from
12 primary health care centres. We assessed weight, height, body mass index (BMI), waist circumference (WC) and
waist-to-height ratio (WHtR). The pulmonary functional parameters were forced vital capacity (FVC), forced expiratory
volume in 1 s (FEV1) and FEV1/FVC ratio.
Results: In this cohort of smokers, 22.2% of individuals had central obesity. FVC% was inversely associated with all
anthropometric measures (BMI, WC and WHtR) in the overall population and in men; in women, only BMI was
associated with FVC%. FEV1% was inversely associated to BMI and WC in the overall population, and to all
anthropometric measures in men. Furthermore, both BMI and obesity were positively associated with FEV1/FVC
ratio overall and when stratified by sex; this suggests a restrictive pattern explained by the altered ventilator
mechanics experienced by people with obesity.
Conclusion: In a Mediterranean population of smokers without respiratory symptoms, abdominal obesity,
evaluated not only by BMI and WC but also WHtR, is inversely associated with lung function. Fat distribution
appears more strongly related to pulmonary function parameters in men than in women. In smokers with high
values for WC, WHtR and BMI, assessment of lung function is recommended.
Trial registration: Current Controlled Trials NCT01194596. Registered 2 September 2010.
Keywords: Lung function test, Overweight, Obesity, Waist circumference, Tobacco smoke
Background
Smoking is an established cause of diseases and is re-
sponsible for most of the avoidable deaths in smokers
due to cardiovascular diseases, respiratory diseases and
cancer [1]. Tobacco smokers have reduced lung function,
characterized by decreased forced expiratory volume after
one second (FEV1) and forced vital capacity (FVC) in
diagnostic tests, and smoking has been associated with en-
vironmental risks, genetic disorders, respiratory infections,
poor dietary habits and obesity [2]. However, other factors
such as body weight can exert an influence on lung func-
tion [3]. Specifically, excess weight has a negative impact
on the respiratory system due to its effect on gas ex-
change, respiratory mechanics, muscular endurance and
breath control [4, 5]. No consensus exists about the
physiopathological mechanisms by which excess weight
leads to respiratory complications, although it seems that
these include mechanical impact on the diaphragm
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(impeding descent into the abdominal cavity) or on the
chest wall (changes in compliance, the work of breathing
and elastic recoil) [6].
Respiratory complications have been consistently re-
ported in patients with obesity, a chronic disease char-
acterized by the excessive accumulation of body fat and
associated with a reduction in lung volume. Body fat
can be measured using the body mass index (BMI) and
classified into categories according to World Health
Organization criteria [7]. The role of BMI relative to
the risk of impaired lung function has been well studied.
The most consistent effect is an exponential decrease in
FEV1% and in functional residual capacity with increasing
BMI [8–11]. On the other hand, a low BMI is associated
with increased risk of mortality and is considered a nega-
tive prognostic factor for survival based on the degree of
lung dysfunction [6, 12].
Nevertheless, studies using weight and BMI as the sin-
gle relevant measurements of adiposity while ignoring
other aspects of body composition, such as visceral fat
or fat distribution, may miss the true dose–response curve
between the distribution of adiposity and increased risk of
disease or all-cause mortality. A recent systematic review
and meta-analysis of the impact of adiposity distribution
has clearly shown a significant inverse relationship be-
tween waist circumference (WC) and pulmonary function,
with a greater effect size in men [13]. Furthermore, waist-
to-height ratio (WHtR) and other indexes of fat distri-
bution have been suggested to better identify high-risk
subjects of different pathologies [14, 15]. WHtR has the
benefit of adjusting WC according to height, a meas-
urement that remains quite unchanged in adults; this
reinforces the importance of changes in WC measure-
ment. These newer indexes have even replaced BMI in
several definitions for clinical diagnosis of metabolic
syndrome that consider fat distribution a more accurate
predictor of diabetes of cardiovascular disease [16]; how-
ever, they are not widely used in studies of respiratory
function or diseases.
The aim of the present study was to assess the associ-
ation between body weight, new indexes of fat distribution
and lung function in a Mediterranean population of
smokers with no diagnosis of respiratory disease.
Methods
Study design
A cross-sectional study was performed with baseline
data from a representative sample of the ESPITAP study
(Spanish acronym for “Effectiveness of Smoking Cessa-
tion Advice Combined with Spirometric Results in Adult
Smokers”). This multicentre, randomized, clinical trial
aimed to evaluate the effectiveness in the primary care set-
ting of a structured motivational intervention and feedback
on spirometry data to achieve smoking cessation, compared
with usual clinical practice and assessed with respect to quit
rates at 12 months after the intervention. The detailed
protocol of the ESPITAP study has been previously
published [17].
Study subjects
Of the 195,343 patients aged 18 years and older from 12
primary care practices in the province of Tarragona
(Spain) managed by the Catalan Health Institute who
were randomized to the ESPITAP study groups, 738
were selected. Candidates for participation were smokers
who visited a centre for any reason during regular office
hours, met all inclusion criteria and none of the exclusion
criteria (detailed below), and signed informed consent.
Inclusion criteria
Aged 35 to 70 years, current smoker (defined as having
smoked daily during the past month, regardless of the
quantity), cumulative consumption of more than 10
pack-years (defined as the daily average of cigarettes
smoked, multiplied by the number of years of smoking,
divided by 20 cigarettes in a pack). Exclusion criteria:
any evidence of previous diagnosis of a respiratory dis-
ease, functional pulmonary testing conducted within the
previous 12 months, presence of any chronic or terminal
condition that would affect the baseline parameters or
complicate the testing and analysis to be conducted during
the study period, impossibility of completing follow-up for
any reason, or patient refusal to participate in the study.
Measurements
The baseline examination included a structured question-
naire designed to collect the necessary data: sociodemo-
graphic, history of diseases, medications and symptoms,
alcohol consumption (standard drink unit/week), physical
activity (hours/week), current daily smoking habit (cig-
arettes per day) and accumulated consumption (lifetime
tobacco exposure in pack-years).
Lung function
Spirometry and bronchodilator tests were administered
using a Datospir-600 ultrasound pneumotachograph
(SIBELMED, S.A.), following a standardized procedure
according to current recommendations [18]. The following
criteria were used to determine normal pneumotachogra-
phy values: FEV1 ≥ 80% of the predicted value, FVC ≥ 80%
of the predicted value, and FEV1/FVC ≥ 0.7 [19].
Anthropometry and body composition
During a physical examination, height (m) and weight (kg)
were measured with the participant in light clothing and
no shoes, using calibrated scales and a wall-mounted sta-
diometer, respectively; BMI was calculated as the weight
(kilograms) divided by the square of the height (meters).
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World Health Organization criteria were used to classify
the population according to weight status (normal weight,
BMI <25.0 kg/m2; overweight, BMI 25.0–29.9 kg/m2 and
obesity, BMI ≥30.0 kg/m2) [7]; WC was measured midway
between the lowest rib and the iliac crest using an an-
thropometric tape; the WHtR was calculated as WC
divided by height, both in centimetres.
Sample size
Accepting an alpha risk of 0.05 in a two-sided test with
243 subjects in the first group (normal weight) and 175
in the second group (obesity), the statistical power was
greater than 99% to recognize as statistically significant a
difference of means (97.9 of FVC% in normal-weight
group and 87.8 of FVC% in obesity group). Moreover,
accepting an alpha risk of 0.05 in a two-sided test with
243 subjects in the first group (normal weight) and 303
in the second group (overweight), the statistical power
was 98% to recognize as statistically significant a differ-
ence of means (97.9 of FVC% in normal weight group
and 92.8 of FVC% in overweight group).
Statistical analysis
Quantitative variables were expressed as mean and
standard deviation (SD) or median and range depending
on the normal distribution of variable. We evaluated the
association of categories of body weight and fat distribu-
tion measures with lung function according to the spirom-
etry results. First, a Pearson correlation was performed to
investigate association between weight, height, BMI, WC
and WHtR and FVC%, FEV1% and FEV1/FVC ratio. Later,
a multivariate linear regression analysis was performed for
all participants and for men and women separately, apply-
ing the Full Maximum likelihood method of estimation.
BMI <25 kg/m2 was used as reference value.
We applied Holm-Bonferroni corrections for multiple
testing to p-values resulting from the Pearson correl-
ation [20].
All statistical tests were 2-sided at the 5% significance
level. Analyses were carried out using the Stata/MP 14.1
version (Stata Corp).
Results
A total of 738 participants (52.3% men) were included.
The baseline characteristics of the study participants are
shown in Table 1. There were no significant differences
between men and women in age, sociodemographic
data, medical history or BMI, though men tended to be
taller and heavier than women. Approximately 41% of
the study population was overweight and 24% was obese,
with higher values in men. The mean (SD) age of smok-
ing onset was lower in men (17.10 ± 4.73 years vs. 18.71
± 6.44 for women) and women smoked less (17.63 ± 9.30
cigarettes a day vs. 20.72 ± 11.94 for men). FVC%, FEV1 %
and FEV1/FVC ratio were lower in men.
The correlation between the anthropometric measures
and lung function are shown in Table 2. FVC % was in-
versely correlated with body weight (r = −0.203), BMI
(r = −0.236), WC (r = −0.267) and WHtR (r = −0.261),
but only in men. Furthermore, FEV1% was associated
with WC (r = −0.226) and WHtR (r = −0.218) only in
men. No association was found between FEV1/FVC ra-
tio and the adiposity measures (BMI, WC and WHtR).
A multivariate linear regression analysis of lung function
parameters and anthropometric measures, overall and sep-
arately for men and women, are shown in Table 3. FVC%
was inversely and significantly associated with all anthropo-
metric measures in the overall population (WHtR, p =
0.002; WC, p <0.001; continuous BMI, p <0.001; BMI ≥30,
p <0.001) and men (WHtR, p = 0.001; WC, p <0.001; con-
tinuous BMI, p <0.001; BMI ≥30, p <0.001). By contrast,
only continuous BMI was inversely associated with FVC%
in women (p = 0.016). Likewise, FEV1% was inversely asso-
ciated only with WC and continuous BMI in the overall
population (p = 0.005 and p = 0.024, respectively), but with
all anthropometric measures in men (WHtR, p = 0.007;
WC, p = 0.002; continuous BMI, p = 0.029; BMI ≥30,
p = 0.054). In women, none of the anthropometric in-
dices was significantly associated with FEV1%. Finally,
FEV1/FVC ratio was positively associated with BMI
categorization and continuous BMI in the overall popula-
tion and in men and women when analysed separately.
Discussion
This study, conducted in a Mediterranean population of
smokers without pulmonary disease, showed that over-
weight, obesity and pattern of body fat distribution are
inversely related to lung function. A positive association
was found between FEV1/FVC ratio and BMI, over-
weight and obesity categories in both sexes. Moreover, a
negative correlation was found between BMI, WC and
WHtR and both FVC% and FEV1% in all smokers, but
especially in men. These new adiposity markers provide
evidence from a Mediterranean population of smokers
and complement the findings of previous cross-sectional
and prospective studies in other populations showing
that an excess of adipose tissue and its distribution pat-
tern are negatively related to pulmonary function, a
basic indicator of respiratory health [8, 9, 21, 22].
The present study has both limitations and strengths
to consider. Cross-sectional analysis was used to assess
the ability of adiposity marker measures to predict a pul-
monary function disorder, making inference of causality
difficult. Further longitudinal analysis will provide stron-
ger evidence of these associations. Smoking status,
which has a detrimental effect on the lungs, is a poten-
tial confounding factor in the relationship between BMI,
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Table 1 Characteristics and lung function measures of the study sample, overall and separately for men and women
Variables Men (n = 386) Women (n = 352) All (n = 738)
Sociodemographic
Age, years 52.87 ± 8.23 48.90 ± 7.39 50.98 ± 8.08
Marital status, n (%)
Married 299 (77.5) 226 (64.2) 525 (71.1)
Widower 3.0 (0.8) 19 (5.4) 22 (3.0)
Single 46 (12.0) 39 (11.1) 85 (11.6)
Separated/Divorced 35 (9.1) 66 (18.9) 101 (13.8)
Social classa, n (%)
High 62 (16.1) 51 (14.5) 113 (15.4)
Medium 176 (46.0) 148 (42.0) 324 (43.9)
Low 145 (37.6) 151 (42.9) 296 (40.1)
Medical history, n (%)
Diabetes mellitus 49 (12.7) 18 (5.1) 67 (9.1)
Dyslipidaemia 115 (29.8) 64 (18.2) 179 (24.3)
Hypertension 112 (29.0) 68 (19.3) 180 (24.4)
Cardiovascular disease 18 (4.7) 4 (1.1) 22 (3.0)
Central obesity 72 (18.6) 92 (26.1) 164 (22.2)
Health habits
Alcohol consumption, standard drink/week 7 (0–9) 0 (0–2) 1 (0–9)
Physical activity, hours/week 2.42 ± 0.26 2.20 ± 0.19 2.31 ± 0.16
Smoking
Start smoking age, years 17.10 ± 4.73 18.71 ± 6.44 17.87 ± 5.65
Current consumption, cigarettes/day 20.72 ± 11.94 17.63 ± 9.30 19.25 ± 10.87
Cumulative consumption, pack-years 36.77 ± 23.55 26.96 ± 16.62 32.09 ± 21.10
Anthropometric and body composition
Weight, kg 80.38 ± 13.46 66.82 ± 14.15 73.92 ± 15.36
Height, cm 170.30 ± 6.93 158.35 ± 6.79 164.61 ± 9.09
BMI, kg/m2 27.63 ± 0.22 26.65 ± 0.28 27.16 ± 0.17
BMI categorizationb, n (%)
< 25.0 kg/m2 90 (23.3) 153 (44.5) 243 (32.9)
25.0–29.9 kg/m2 184 (47.7) 119 (33.8) 303 (41.1)
≥ 30.0 kg/m2 102 (26.4) 73 (21.2) 175 (23.7)
Waist circumference, cm 98.75 ± 10.44 92.27 ± 16.55 96.0 ± 13.73
Waist-to-height ratio 0.58 ± 0.06 0.59 ± 0.10 0.58 ± 0.82
Lung function parameters
FVC, % of predicted 89.14 ± 0.84 98.10 ± 0.77 93.49 ± 0.59
FEV1, % of predicted 90.50 ± 0.96 99.73 ± 0.82 94.93 ± 0.66
FEV1/FVC ratio (%) 76.13 ± 0.40 78.59 ± 0.35 77.32 ± 0.27
Data are presented as number of patients (%) or mean ± standard deviation or median ± range depending on the type of variable
BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, ppm Parts per million, FVC Forced vital capacity, FEV1 Maximum expiratory
volume in the first second of a forced exhalation
aAccording to the National Occupational Classification proposed by the Spanish Society of Epidemiology and the Spanish Society of Family and Community
Medicine [41]
bAccording to the WHO classifications of body weight [7]
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Table 2 Correlation between lung function and anthropometric parameters, overall and separately for men and women
Variables Weight Height BMI Waist circumference Waist-to-height ratio
FVC % Predicted
All −0.315** −0.203** −0.243** −0.261** −0.196**
Women −0.241** −0.079 −0.215** −0.159 −0.184
Men −0.203** 0.024 −0.236** −0.267** −0.261**
FEV1 % Predicted
All −0.238** −0.201** −0.153** −0.209** −0.132
Women −0.151* −0.089 −0.115 −0.087 −0.087
Men −0.134 −0.001 −0.148 −0.226** −0.218**
FEV1/FVC ratio
All 0.030 −0.137** 0.122 0.011 0.074
Women 0.121 −0.073 0.163 0.127 0.173
Men 0.120 −0.001 0.131 0.001 −0.018
Values represent the correlation coefficients. *p < 0.05, **p < 0.001
BMI, body mass index, FVC forced vital capacity, FEV1 maximum expiratory volume in the first second of a forced exhalation
Table 3 Multivariate linear regression analysis of lung function and anthropometric parameters, overall and separately for men and women
Variables Male Female All
β 95% CI p values β 95% CI p values β 95% CI p values
FVC % Predicted
Waist-to-height −61.48 −98.00, −24,96 0.001 −14.76 −36.94, 7.41 0.190 −26.8 −46.61, −6.93 0.002
Waist circumference −0.39 −0.60, −0.18 <0.001 −0.07 −0.21 0.07 0.328 −0.22 −0.34, −0.10 <0.001
BMI, continuous −0.79 −1.19, −0.39 <0.001 −0.37 −0.67, −0.07 0.016 −0.59 −0.83, −0.34 <0.001
BMI categorizationa
< 25.0 kg/m2 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
25.0–29.9 kg/m2 −4.67 −8.67, −0.66 0.023 −1.51 −4.94, 1.92 0.388 −4.21 −6.81, −1.60 0.002
≥ 30.0 kg/m2 −9.19 −13.82, −4.54 <0.001 −3.21 −7.45, 1.04 0.138 −67.25 −10.38, −4.13 <0.001
FEV1 % Predicted
Waist-to-height −59.91 −102.94, −16.88 0.007 −2.99 −27.32, 21.34 0.808 −16.94 −39.77, 5.88 0.145
Waist circumference −0.40 −0.65, −0.15 0.002 −0.02 −0.17, 0.13 0.787 −0.20 −0.33, −0.06 0.005
BMI, continuous −0.52 −0.99, −0.05 0.029 −0.10 −0.41, 0.22 0.547 −0.32 −0.59, −0.04 0.024
BMI categorizationa
< 25.0 kg/m2 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
25.0–29.9 kg/m2 −0.78 −5.52, 3.96 0.609 1.43 −2.18, 5.04 0.436 −1.01 −3.95, 1.93 0.502
≥ 30.0 kg/m2 −5.39 −10.87, 0.99 0.054 0.08 −4.38, 4.54 0.971 −2.77 −6.25, 0.70 0.118
FEV1/FVC ratio
Waist-to-height 1.13 −17.93, 20.20 0.907 11.58 1.46, 21.70 0.025 9.58 −0.16, 19.32 0.054
Waist circumference 0.01 −0.10, 0.12 0.917 0.05 −0.01, 0.12 0.113 0.02 −0.04, 0.08 0.512
BMI, continuous 0.24 0.11, 0.38 <0.001 0.31 0.11, 0.50 0.002 0.26 0.14, 0.37 <0.001
BMI categorizationa
< 25.0 kg/m2 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
25.0–29.9 kg/m2 3.76 1.79, 5.73 <0.001 2.23 0.71, 3.75 0.004 2.43 1.20, 3.65 <0.001
≥ 30.0 kg/m2 3.81 1.53, 6.09 0.001 3.10 1.17, 4.93 0.002 2.89 1.42, 4.36 <0.001
Adjusted by social class, smoking cumulative consumption, physical activity, alcohol consumption, medical history hypertension, diabetes mellitus
and dyslipidemia
FVC Forced vital capacity, FEV1 Maximum expiratory volume in the first second of a forced exhalation; β: regression coefficient for each exposure variable,
CI Confidence interval, BMI Body mass index
aAccording to the WHO classifications of body weight: normal weight (<25.0 kg/m2), overweight (25.0–29.9 kg/m2) and obese (≥30.0 kg/m2) [7]
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WC, WHtR and pulmonary function. Furthermore, our
results pertain to a specific cohort of adult smokers
(aged 35–70 years), a population with a high risk of lung
disease [2]. The relationship between smoking and worse
lung function is no longer subject to debate, given the
available epidemiological, morphological and genetic evi-
dence. However, more recent studies are demonstrating
the importance of additional factors such as abdominal
adiposity markers [6]. It is possible that impaired lung
function parameters were better associated with WC or
WHtR than with BMI because smokers tend to have a
lower BMI [23]. On the other hand, BMI is the only
measure of obesity reported in several other population-
based studies [8, 24]. Therefore, a strength of our work
is that few studies have evaluated the association be-
tween WHtR and lung function.
Our study showed that highly specific markers of in-
creased abdominal adiposity such as WC and/or WHtR,
already proposed as better adiposity indicators than BMI
[13, 25], were associated with lower FVC% and FEV1%
values. Furthermore, a recent meta-analysis supports the
use of WC as a pulmonary risk indicator because high
WC values are associated with pulmonary dysfunction
[13]. Results of the present study also support the use of
WHtR as a new adiposity distribution marker involved
in pulmonary function, amplifying the hypothesis previ-
ously tested for cardiovascular diseases [26]. Those au-
thors recommend using WHtR, the correction of WC
according to the height of the individual, because this
measurement remains quite unchanged in adults, which
reinforces the importance of changes in WC measure-
ment. WHtR has been inversely associated with cardio-
vascular risk [25], and now also with lung function in
the present study.
In our analysis stratified by sex, the inverse association
of WC and WHtR with impaired lung function (FEV1%
and FVC %) was apparent in men but not in women.
This finding is consistent with results from several other
studies [8, 11, 27, 28], and supports the hypothesis that a
sex-related difference in the pattern of fat distribution is
one of the explanations for the sex difference in lung
function impairment. Nonetheless, other studies have
shown the opposite results. For example, in a cohort of
patients with metabolic syndrome, pulmonary function
was significantly lower in women than in men [29]. Al-
though it was unclear why sex would be associated with
differences in the effect of body fat distribution on pul-
monary function, some possible explanations may be of-
fered. Sex-based differences in lifestyle factors, hormonal
system and pulmonary structure could affect pulmonary
function. Another possible mechanism is a difference in
how fat distribution associated with weight gain affects
the thoracic mechanism in men vs. women, so that the
location of fat deposition in women does not adversely
affect lung function [24]. Cross-sectional and longitu-
dinal studies of lung function suggest that the effects on
respiratory mechanics might be more pronounced in
men than in women for any given body fat distribution
pattern [9, 11, 27, 28]. It has also been suggested that
lung function is influenced by sex differences, perhaps
due to a lower functional impairment (smoke-induced)
in women smokers, compared to men who smoke [30];
however, large epidemiological studies show that suscep-
tibility to tobacco is similar in both sexes [31].
BMI category in smokers is associated with worse
health status and impaired lung function. Recent find-
ings delineate a “U-shaped” association between BMI
and extreme weight categories, such that both the obese
(BMI ≥30 kg/m2) and the lean to underweight (BMI
<25 kg/m2) smokers had lower FEV1 and worse health
status [32]. In our study, the results confirm that over-
weight and obesity are positively associated with FEV1/
FVC ratio in both sexes. Some studies that included
measurements of central adiposity have also observed
that these tend to correlate with worse lung function,
even in non-obese individuals [33]. However, other au-
thors found no significant differences in FEV1/FVC ratio
between obese and non-obese individuals [34]. Although
the pattern of fat distribution appears to have a more
significant influence on FEV1% and FVC% than more
commonly used measures of general obesity such as
continuous BMI, our results show that BMI >25 kg/m2
has a greater direct effect on the FEV1/FVC ratio. This
spirometric variable discriminates obstructive ventilation
disorder, while a reduction in FVC% accompanies the re-
duction or maintenance of FEV1%, suggesting a restrict-
ive pattern that can be explained by the alteration in
ventilator mechanics experienced by people with obesity
[35, 36]. When abdominal fat deposition occurs and
BMI increases, the descent of the diaphragm during
inspiration is limited, reducing the expiratory reserve
volume by displacing the diaphragm upward and redu-
cing functional volume in the thoracic cavity [6, 9, 12].
Another possible mechanism is that chest-wall adiposity
may impede expansion and excursion of the rib cage,
through a direct loading effect or by altering intercostal
muscle function, which decreases inspiratory muscle activ-
ity [37, 38]. In addition to these mechanical processes,
lung function may also be affected by chronic low-grade
inflammatory processes that accompany obesity. It has
been shown that excess body fat is associated with
markers of systemic and vascular inflammation such as C-
reactive protein, interleukin-6, tumour necrosis factor-α,
leptin and adiponectin [39]. As a whole, the available data
confirm a much more complex relationship between
anthropometric changes and lung function than can be
ascribed solely to inflammatory effects, and growing
evidence suggests that an interaction of adipokine disorder,
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mechanical disturbances and changes in muscle mass
results in a combined effect on lung impairment and its
manifestations [40].
Conclusions
In a Mediterranean population of smokers without re-
spiratory symptoms, abdominal obesity has a negative
impact on lung function. Central fat distribution appears
to have a stronger relationship with pulmonary func-
tional parameters in men than in women. In addition to
BMI, other indexes of fat distribution (WC and WHtR)
can be easily obtained during routine clinical practice
and can be useful tools to indicate the advisability of car-
rying out a full assessment. Sensitization of primary care
physicians to the identification of smokers with these
conditions might increase referrals for lung function
testing and lead to earlier diagnosis and appropriate
patient management. What is known is that quitting
smoking and losing weight are likely the best way to
improve lung health in this rapidly growing patient
population.
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